Circio Holding ASA is a biotechnology company, which engages in developing novel circular RNA and immunotherapy medicines. It focuses on developing a cancer vaccine, TG01, targeting KRAS driver mutations. The company was founded on October 1, 2010 and is headquartered in Lysaker, Norway.